AC Immune S.A. (ACIU)
ACIU Stock Price Chart
Explore AC Immune S.A. interactive price chart. Choose custom timeframes to analyze ACIU price movements and trends.
ACIU Company Profile
Discover essential business fundamentals and corporate details for AC Immune S.A. (ACIU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Sept 2016
Employees
133.00
Website
https://www.acimmune.comCEO
Andrea Pfeifer
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
ACIU Financial Timeline
Browse a chronological timeline of AC Immune S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$0.23, while revenue estimate is $805.88K.
Earnings released on 5 Aug 2025
EPS came in at -$0.25 falling short of the estimated -$0.20 by -25.00%, while revenue for the quarter reached $1.64M , beating expectations by +420.50%.
Earnings released on 30 Apr 2025
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%, while revenue for the quarter reached $1.16M , beating expectations by +145.43%.
Earnings released on 13 Mar 2025
EPS came in at -$0.18 surpassing the estimated -$0.21 by +14.29%, while revenue for the quarter reached $1.25M , beating expectations by +52.78%.
Earnings released on 5 Nov 2024
EPS came in at $0.05 surpassing the estimated -$0.20 by +125.00%, while revenue for the quarter reached $29.69M , beating expectations by +2.04K%.
Earnings released on 6 Aug 2024
EPS came in at -$0.25 falling short of the estimated $0.42 by -159.52%, while revenue for the quarter reached $766.74K , missing expectations by -99.24%.
Earnings released on 13 May 2024
EPS came in at -$0.21 falling short of the estimated -$0.15 by -40.00%.
Earnings released on 14 Mar 2024
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $17.30M , beating expectations by +51.34%.
Earnings released on 3 Nov 2023
EPS came in at -$0.20 falling short of the estimated -$0.02 by -754.34%.
Earnings released on 4 Aug 2023
EPS came in at -$0.22 matching the estimated -$0.22.
Earnings released on 28 Apr 2023
EPS came in at -$0.23 surpassing the estimated -$0.24 by +4.17%.
Earnings released on 16 Mar 2023
EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%, while revenue for the quarter reached $1.08K , missing expectations by -99.94%.
Earnings released on 28 Oct 2022
EPS came in at -$0.17 surpassing the estimated -$0.24 by +29.17%, while revenue for the quarter reached $4.00M , beating expectations by +1.03K%.
Earnings released on 28 Jul 2022
EPS came in at -$0.24 matching the estimated -$0.24.
Earnings released on 28 Apr 2022
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%.
Earnings released on 22 Mar 2022
EPS came in at -$0.28 falling short of the estimated $0.10 by -380.00%.
Earnings released on 8 Nov 2021
EPS came in at -$0.24 surpassing the estimated -$0.29 by +17.24%.
Earnings released on 4 Aug 2021
EPS came in at -$0.29 falling short of the estimated -$0.22 by -31.82%.
Earnings released on 28 Apr 2021
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%.
Earnings released on 23 Mar 2021
EPS came in at -$0.30 falling short of the estimated -$0.29 by -3.45%, while revenue for the quarter reached $1.07M .
Earnings released on 13 Nov 2020
EPS came in at -$0.28 falling short of the estimated -$0.24 by -16.67%, while revenue for the quarter reached $1.22M , beating expectations by +13.27%.
ACIU Stock Performance
Access detailed ACIU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.